Immunovia's CEO Jeff Borcherding sees the rights issue as the next step following the launch of PancreaSure and the submission of the application for Medicare reimbursement. The capital will be used to...
Published
Watch a new presentation on the company's strategy and operational activities to increase the use of PancreaSure, achieve reimbursement and enable earlier cancer treatment for patients in the USA.
Published
On November 2nd 2026, CEO Jeff Borcherding and CFO Adam Bäckström presented the report. Watch the webcast for the presentation here.
Published
Immunovia is carrying out a rights issue of approximately SEK 63 million, backed by subscription undertakings and guarantees covering 80 percent of the issue, to fund continued U.S. commercialization of...
Published
A new analysis published in the Journal of Clinical Medicine shows PancreaSure detects Stage I and II pancreatic cancer with 77.5% sensitivity and 93.6% specificity in individuals at hereditary or familial...
Published
A formal LCD request has been submitted to Medicare – a key milestone toward coverage for PancreaSure, targeting the age group that accounts for three in four pancreatic cancer deaths in the U.S.
Published
A new survey of 392 high-risk individuals finds that 91% are comfortable using a blood-based test like PancreaSure for early detection, preferring it as a complement to existing imaging.
Published
2025 – The year Immunovia launched PancreaSure and transitioned to a commercial company.
Published
Watch CEO Jeff Borcherding present the company at Aktiespararna’s Life Science theme night from January 26 2026.
Published
